

What is claimed:

1. (original) A method for determining the propensity of a test compound to cause depletion of reticulocytes in a subject, the method comprising:
 - a) administering an effective amount of a test compound to a test subject for a selected period of time;
 - b) determining the expression level of a plurality of indicator genes, wherein said indicator genes exhibit a statistically significant change in expression level in response to administration of a plurality of compounds known to cause depletion of reticulocytes in a test subject;
 - c) determining the difference between the expression level of each indicator gene and a control expression level of said indicator gene;
 - d) determining the statistical significance of the difference between the expression level of each indicator gene and a control expression level of said indicator gene;
 - e) assigning a probability of reticulocyte depletion to said test compound if a substantial fraction of said plurality of said indicator genes exhibit a statistically significant change in expression level.
2. (original) The method of claim 1, wherein said selected period of time is three days.
3. (original) The method of claim 1, wherein said selected period of time is five days.
4. (withdrawn) A Drug Signature database, comprising:
 - a plurality of Drug Signature records, wherein each Drug Signature record comprises indicia of one compound;
 - indicia of a set of genes that are upregulated in response to administration of said compound, wherein said set of genes distinguishes said compound from all other compounds within said Drug Signature database,
 - further comprising a Reticulocyte Depletion Signature.

5. (withdrawn) A method for deriving a Reticulocyte Depletion Signature, the method comprising:

- a) administering an effective amount of a plurality of compounds to test subjects for a selected period of time, said plurality of compounds comprising a plurality of bone marrow toxicants or immunosuppressants that cause reticulocyte depletion and a plurality of control compounds;
- b) identifying a plurality of affected genes, wherein said affected genes exhibit a statistically significant change in expression level in response to administration of said plurality of non-steroidal anti-inflammatory drugs compared to said control compounds; and
- c) identifying the affected genes for which the difference in expression level is statistically significant.

6. (original) The method of claim 1, wherein said probability is evaluated by the method comprising:

- a) deriving a test compound vector representing the expression of said indicator genes in response to said test compound; and
- b) projecting said test compound vector against a signature vector representing the expression of said indicator genes in response to a plurality of compounds known to cause reticulocyte depletion;

wherein the degree of match between the test compound vector and the signature vector indicates the degree to which the test compound will exhibit reticulocyte depletion characteristic of the compounds used to derive the signature vector.

7. (new) The method of claim 1 wherein said plurality of indicator genes comprises aminolevulinate synthase 2 and peripherin.